Zinc finger C4H2-type protein (ZC4H2) (ZC4H2)

Zinc finger C4H2-type protein (ZC4H2) is a nuclear protein essential for the development of the central and peripheral nervous systems, particularly in the formation of the spinal cord and neuromuscular junctions. It acts as a critical co-factor for the E3 ubiquitin ligase RNF220, facilitating the stability of the ligase and the subsequent degradation of various neural patterning factors (UniProt Q9NQZ6). Mutations in the ZC4H2 gene lead to a spectrum of neuromuscular conditions known as ZC4H2-associated rare disorders (ZARD), which include Wieacker-Wolff syndrome and are characterized by arthrogryposis multiplex congenita and intellectual disability (PubMed 23453666). While there are currently no FDA-approved drugs that directly target ZC4H2, research is focused on gene replacement therapies and antisense oligonucleotides to restore protein function or levels. The protein's involvement in the BMP and Shh signaling pathways makes it a significant focal point for therapeutic development in rare neurodevelopmental diseases (PubMed 28190456).

Other names

Zinc finger C4H2 domain-containing proteinZNF409KIAA1168Wieacker-Wolff syndrome proteinZARD

There are currently no approved pharmacological agents for ZC4H2; however, experimental approaches include gene replacement therapy to restore functional ZC4H2 protein levels and antisense oligonucleotides (ASOs) to modulate gene expression (PubMed 23453666).